Tests dietary phosphate's effect on exercise and fat in adults
Tests extra dietary phosphate against salt in adults with visceral obesity and inactivity.
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Dallas, United StatesSee the site
- Trial code
- Registry title
- Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
- Status
- Recruiting
- People taking part
- 124 people, planned
- Started
- 14 Sept 2022
- Expected to end
- 30 Mar 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Sodium Phosphate
- Sodium Chloride
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 who are otherwise healthy and have no diabetes, chronic kidney disease or heart disease. Everyone takes sodium phosphate and sodium chloride capsules, each for 4 weeks.
- Age
- 18 Years to 80 Years
- Sex
- All sexes can join.
- Disease stage
- Otherwise healthy people without diabetes, chronic kidney disease or existing cardiovascular disease.
- Earlier treatment
- People taking any medicine that acts on blood vessels and could change how the heart and blood vessels react to exercise cannot join.
- Biomarker or test result
- Serum phosphorus must be between 2.4 and 4.5 mg/dL.
Main reasons for not taking part
- History of heart, lung or chronic kidney disease
- Treatment with blood pressure medicines
- eGFR below 60 mL/min/1.73m2
- Diabetes or another body-wide illness
- Pregnancy, substance abuse, current cigarette use, psychiatric illness or active cancer
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- The randomized crossover trial will be performed in on otherwise healthy subjects without diabetes mellitus, chronic kidney disease (CKD), preexisting cardiovascular disease or treatment with any vasoactive agent that might alter cardiovascular responses to exercise
Who cannot take part
- treatment with antihypertensive medications,
- history of cardiopulmonary disease or chronic kidney disease,
- estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2, (4) diabetes mellitus or other systemic illness,; (5) pregnancy, (6) hypersensitivity to sodium phosphate, (7) any history of substance abuse or current cigarette use, (8) any history of psychiatric illness, (9) history of active malignancy, (10) serum phosphorus < 2.4 or > 4.5 mg/dL
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- University of Texas, SouthwesternDallas, United StatesContact: John Giacona, PA-CTaking people
About the trial
What the trial wants to find out
Studies in mice demonstrated that dietary phosphate (Pi) loading that mimic the level of US adult consumption leads to reduced spontaneous locomotor activity, exercise capacity, and reduced resting metabolic rate when in normal mice by impairing skeletal muscle mitochondrial function and fat oxidation. However, relevance of this findings in humans remains unknown.
The 2 groups in the trial
- Sodium Phosphate (NaPO4) then sodium chloride (NaCl)Treatment being tested
Participants will be asked to take 2 capsules daily of Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) ) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d). Then, participants will be asked to take 2 capsules of Sodium Chloride (NaCl, containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).
Treatment: Sodium Phosphate and Sodium Chloride
- NaCl then NaPO4Treatment being tested
Participants will be asked to take 2 capsules daily of Sodium Chloride (NaCl, containing a total of 372mg of sodium) for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d). Then, participants will be asked to take 2 capsules of Sodium Phosphate daily for 4 weeks Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d).
Treatment: Sodium Phosphate and Sodium Chloride
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
- Plain-language title
- Tests dietary phosphate's effect on exercise and fat in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05147909, who can take part
- Record updated
- 17 February 2026